Neuropeptide Y receptor

neuropeptide Y receptor Y2
neuropeptide Y receptor Y2
Identifiers
Symbol	NPY2R
NCBI gene	4887
HGNC	7957
OMIM	162642
RefSeq	NM_000910
UniProt	P49146
Other data
Locus	Chr. 4 q31
Structures
Search for
Structures	Swiss-model
Domains	InterPro

Search for
Structures	Swiss-model
Domains	InterPro

neuropeptide Y receptor Y1
neuropeptide Y receptor Y1
Identifiers
Symbol	NPY1R
Alt. symbols	NPYR
NCBI gene	4886
HGNC	7956
OMIM	162641
RefSeq	NM_000909
UniProt	P25929
Other data
Locus	Chr. 4 q31.3-q32
Structures
Search for
Structures	Swiss-model
Domains	InterPro

Neuropeptide Y receptors are a family of receptors belonging to class A G-protein coupled receptors and they are activated by the closely related peptide hormones neuropeptide Y, peptide YY and pancreatic polypeptide.^[1] These receptors are involved in the control of a diverse set of behavioral processes including appetite, circadian rhythm, and anxiety.^[2]^[3]^[4]^[5]^[6]^[7]

pancreatic polypeptide receptor 1

Identifiers

Symbol

PPYR1

Alt. symbols

NPY4R, Y4, PP1

Other data

Chr. 10 q11.2

Search for
Structures	Swiss-model
Domains	InterPro

neuropeptide Y receptor Y5

Identifiers

Symbol

NPY5R

Other data

Chr. 4 q31-q32

Search for
Structures	Swiss-model
Domains	InterPro

Activated neuropeptide receptors release the G_i subunit from the heterotrimeric G protein complex. The G_i subunit in turn inhibits the production of the second messenger cAMP from ATP.

Only the crystal structure of Y1 in complex with two antagonist is available.^[8]

Types

There are five known mammalian neuropeptide Y receptors designated Y₁ through Y₅.^[9] Four neuropeptide Y receptors each encoded by a different gene have been identified in humans, all of which may represent therapeutic targets for obesity and other disorders.^[10]^[11]^[12]

Y₁ - NPY1R
Y₂ - NPY2R
Y₄ - PPYR1
Y₅ - NPY5R

Antagonists

References

^ Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors". Pharmacol. Rev. 50 (1): 143–50. PMID 9549761.
^ Heilig M (August 2004). "The NPY system in stress, anxiety and depression". Neuropeptides. 38 (4): 213–24. doi:10.1016/j.npep.2004.05.002. PMID 15337373. S2CID 37034137.
^ Harro J (October 2006). "CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies". Amino Acids. 31 (3): 215–30. doi:10.1007/s00726-006-0334-x. PMID 16738800. S2CID 2017793.
^ Eaton K, Sallee FR, Sah R (2007). "Relevance of neuropeptide Y (NPY) in psychiatry". Current Topics in Medicinal Chemistry. 7 (17): 1645–59. doi:10.2174/156802607782341037. PMID 17979774.
^ Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). "Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide". Recent Patents on CNS Drug Discovery. 1 (3): 315–24. doi:10.2174/157488906778773689. PMID 18221213.
^ Vona-Davis LC, McFadden DW (2007). "NPY family of hormones: clinical relevance and potential use in gastrointestinal disease". Current Topics in Medicinal Chemistry. 7 (17): 1710–20. doi:10.2174/156802607782340966. PMID 17979780.
^ Lindner D, Stichel J, Beck-Sickinger AG (September 2008). "Molecular recognition of the NPY hormone family by their receptors". Nutrition (Burbank, Los Angeles County, Calif.). 24 (9): 907–17. doi:10.1016/j.nut.2008.06.025. PMID 18725086.
^ Yang Z, Han S, Keller M, Kaiser A, Bender BJ, Bosse M, Burkert K, Kögler LM, Wifling D, Bernhardt G, Plank N, Littmann T, Schmidt P, Yi C, Li B, Ye S, Zhang R, Xu B, Larhammar D, Stevens RC, Huster D, Meiler J, Zhao Q, Beck-Sickinger AG, Buschauer A, Wu B (April 2018). "1 receptor". Nature. 556 (7702): 520–524. doi:10.1038/s41586-018-0046-x. PMC 5920736. PMID 29670288.
^ Larhammar D, Salaneck E (2004). "Molecular evolution of NPY receptor subtypes". Neuropeptides. 38 (4): 141–51. doi:10.1016/j.npep.2004.06.002. PMID 15337367. S2CID 43696257.
^ Kamiji MM, Inui A (October 2007). "Neuropeptide y receptor selective ligands in the treatment of obesity". Endocrine Reviews. 28 (6): 664–84. doi:10.1210/er.2007-0003. PMID 17785427.
^ MacNeil DJ (2007). "NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs". Current Topics in Medicinal Chemistry. 7 (17): 1721–33. doi:10.2174/156802607782341028. PMID 17979781.
^ Kamiji MM, Inui A (2007). "NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?". Current Topics in Medicinal Chemistry. 7 (17): 1734–42. doi:10.2174/156802607782340957. PMID 17979782.

External links

"Neuropeptide Y Receptors". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03. Retrieved 2007-10-25.
Neuropeptide+Y+Receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

This transmembrane receptor-related article is a stub. You can help Wikipedia by expanding it.

[pmid9549761-1] Michel MC, Beck-Sickinger A, Cox H, Doods HN, Herzog H, Larhammar D, Quirion R, Schwartz T, Westfall T (March 1998). "XVI. International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors". Pharmacol. Rev. 50 (1): 143–50. PMID 9549761.

[pmid15337373-2] Heilig M (August 2004). "The NPY system in stress, anxiety and depression". Neuropeptides. 38 (4): 213–24. doi:10.1016/j.npep.2004.05.002. PMID 15337373. S2CID 37034137.

[pmid16738800-3] Harro J (October 2006). "CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies". Amino Acids. 31 (3): 215–30. doi:10.1007/s00726-006-0334-x. PMID 16738800. S2CID 2017793.

[pmid17979774-4] Eaton K, Sallee FR, Sah R (2007). "Relevance of neuropeptide Y (NPY) in psychiatry". Current Topics in Medicinal Chemistry. 7 (17): 1645–59. doi:10.2174/156802607782341037. PMID 17979774.

[pmid18221213-5] Xapelli S, Agasse F, Ferreira R, Silva AP, Malva JO (November 2006). "Neuropeptide Y as an endogenous antiepileptic, neuroprotective and pro-neurogenic peptide". Recent Patents on CNS Drug Discovery. 1 (3): 315–24. doi:10.2174/157488906778773689. PMID 18221213.

[pmid17979780-6] Vona-Davis LC, McFadden DW (2007). "NPY family of hormones: clinical relevance and potential use in gastrointestinal disease". Current Topics in Medicinal Chemistry. 7 (17): 1710–20. doi:10.2174/156802607782340966. PMID 17979780.

[pmid18725086-7] Lindner D, Stichel J, Beck-Sickinger AG (September 2008). "Molecular recognition of the NPY hormone family by their receptors". Nutrition (Burbank, Los Angeles County, Calif.). 24 (9): 907–17. doi:10.1016/j.nut.2008.06.025. PMID 18725086.

[8] Yang Z, Han S, Keller M, Kaiser A, Bender BJ, Bosse M, Burkert K, Kögler LM, Wifling D, Bernhardt G, Plank N, Littmann T, Schmidt P, Yi C, Li B, Ye S, Zhang R, Xu B, Larhammar D, Stevens RC, Huster D, Meiler J, Zhao Q, Beck-Sickinger AG, Buschauer A, Wu B (April 2018). "1 receptor". Nature. 556 (7702): 520–524. doi:10.1038/s41586-018-0046-x. PMC 5920736. PMID 29670288.

[pmid15337367-9] Larhammar D, Salaneck E (2004). "Molecular evolution of NPY receptor subtypes". Neuropeptides. 38 (4): 141–51. doi:10.1016/j.npep.2004.06.002. PMID 15337367. S2CID 43696257.

[pmid17785427-10] Kamiji MM, Inui A (October 2007). "Neuropeptide y receptor selective ligands in the treatment of obesity". Endocrine Reviews. 28 (6): 664–84. doi:10.1210/er.2007-0003. PMID 17785427.

[pmid17979781-11] MacNeil DJ (2007). "NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs". Current Topics in Medicinal Chemistry. 7 (17): 1721–33. doi:10.2174/156802607782341028. PMID 17979781.

[pmid17979782-12] Kamiji MM, Inui A (2007). "NPY Y2 and Y4 receptors selective ligands: promising anti-obesity drugs?". Current Topics in Medicinal Chemistry. 7 (17): 1734–42. doi:10.2174/156802607782340957. PMID 17979782.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]